Device Trial Radar · NCT07095894
A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
348
Planned (sponsor's estimate)
Start
Jul 1, 2026
Primary completion
Jul 1, 2029
Study completion Jan 1, 2030
Sponsor
- Lead sponsor
- Jaeb Center for Health ResearchAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 31, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 5 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To date, randomized trials of low-concentration atropine eyedrops and specially designed spectacle lenses to slow the progression of myopia are limited in number and results are inconsistent in non-Asian children. Although results of some recent randomized clinical trials outside the US are promising, additional studies in children are needed to test the safety and efficacy of low-concentration atropine and specially designed spectacle lenses as treatments to slow the progression of myopia during the peak years for eye growth. After a run-in phase to demonstrate adherence with nightly eyedrops (artificial tears) and spectacle correction, children 5 to \<12 years old with myopia of 0.75D to 6.00D cycloplegic spherical equivalent refractive error (SER) and at least 0.75D myopia in both principal meridians of each eye will be randomized in a 2x2 factorial design to treatment with 1) nightly 0.05% atropine or placebo eyedrops, and 2) spectacles with highly aspherical lenslet target (H.A.L.T.) MAX technology or single vision spectacles, and followed every six months for 24 months. Change in axial length over 24 months and change in SER over 24 months are the primary and secondary outcomes, respectively. All children will return for a visit at 30 months (after 6 months of no treatment other than single-vision spectacles alone between 24 and 30 months). The study is funded by the National Eye Institute, part of the NIH, and coordinated by the Jaeb Center for Health Research on behalf of PEDIG. Essilor International, a subsidiary of EssilorLuxottica, the manufacturer of Spectacle lenses with H.A.L.T.\* MAX technology, is providing the eyeglasses and financial support for the study. The 0.05% atropine eye drops used in the study are manufactured by Imprimis Rx, a subsidiary of Harrow, Inc.
Conditions
- Myopia
Interventions
AtropineDrug
Daily 0.05% atropine eyedrops
Spectacles with HALDevice
Spectacle lenses with highly aspherical lenslets (HAL)
Placebo EyedropsDrug
Daily placebo eyedrops
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary efficacy outcome - change in axial lengthTime frame: 24 months.
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
UAB Pediatric Eye Care; Birmingham Health Care
Birmingham, Alabama · Recruiting
University of Arizona
Tucson, Arizona · Recruiting
Marshall B. Ketchum University
Fullerton, California · Recruiting
15 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.